Suzuken Co., Ltd.
Q1 Financial Summary [Japanese GAAP] (Consolidated)
Revenue was 628,962 million yen, up 6.1% YoY. Operating income decreased by 4,190 million yen, ordinary income was 5,074 million yen, and net income attributable to owners of the parent for the quarter was 3,381 million yen. Full-year outlook has revenue of 2,563,000 million yen, operating income of 31,200 million yen, and net income of 25,000 million yen. A stock split is planned, with dividends per share expected to be 60 yen (local currency), and 120 yen on an annual basis.
Key Figures
- Revenue: 628,962 million yen (YoY +6.1%)
- Operating income: 4,190 million yen (YoY △25.0% decrease)
- Net income attributable to owners of the parent: 3,381 million yen (YoY △10.6% decrease)
AI要約
Business performance overview
Revenue is expected to grow year over year with factors supporting growth, while profitability faces cost pressures from rising raw materials and external outsourcing costs, keeping operating income below the previous year's level. Segment-wise, there are mixed dynamics across pharmaceutical wholesale, logistics, and digital business. A stock split is planned, and dividend per share is expected to be 60 yen when considering the split, or 120 yen under normal conditions.
Mid-term plan and capital policy
The mid-term plan targets fiscal year ending March 2029 as the final year, pursuing a 'Health Creation Operating Model' with emphasis on evolving into a next-generation wholesale platform, redesigning the business portfolio, and strengthening the management base. Aiming to create added value through expansion of digital business, advancement of medical DX, and enhanced distribution platforms.
上市会社名
Company overview · Stock price · Financial data · All IR
